Literature DB >> 23860989

West Nile virus: review of the literature.

Lyle R Petersen1, Aaron C Brault, Roger S Nasci.   

Abstract

IMPORTANCE: Since its introduction in North America in 1999, West Nile virus has produced the 3 largest arboviral neuroinvasive disease outbreaks ever recorded in the United States.
OBJECTIVE: To review the ecology, virology, epidemiology, clinical characteristics, diagnosis, prevention, and control of West Nile virus, with an emphasis on North America. EVIDENCE REVIEW: PubMed electronic database was searched through February 5, 2013. United States national surveillance data were gathered from the Centers for Disease Control and Prevention.
FINDINGS: West Nile virus is now endemic throughout the contiguous United States, with 16,196 human neuroinvasive disease cases and 1549 deaths reported since 1999. More than 780,000 illnesses have likely occurred. To date, incidence is highest in the Midwest from mid-July to early September. West Nile fever develops in approximately 25% of those infected, varies greatly in clinical severity, and symptoms may be prolonged. Neuroinvasive disease (meningitis, encephalitis, acute flaccid paralysis) develops in less than 1% but carries a fatality rate of approximately 10%. Encephalitis has a highly variable clinical course but often is associated with considerable long-term morbidity. Approximately two-thirds of those with paralysis remain with significant weakness in affected limbs. Diagnosis usually rests on detection of IgM antibody in serum or cerebrospinal fluid. Treatment is supportive; no licensed human vaccine exists. Prevention uses an integrated pest management approach, which focuses on surveillance, elimination of mosquito breeding sites, and larval and adult mosquito management using pesticides to keep mosquito populations low. During outbreaks or impending outbreaks, emphasis shifts to aggressive adult mosquito control to reduce the abundance of infected, biting mosquitoes. Pesticide exposure and adverse human health events following adult mosquito control operations for West Nile virus appear negligible. CONCLUSIONS AND RELEVANCE: In North America, West Nile virus has and will remain a formidable clinical and public health problem for years to come.

Entities:  

Mesh:

Year:  2013        PMID: 23860989      PMCID: PMC4563989          DOI: 10.1001/jama.2013.8042

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  74 in total

1.  West nile virus RNA not detected in urine of 40 people tested 6 years after acute West Nile virus disease.

Authors:  Katherine B Gibney; Robert S Lanciotti; James J Sejvar; C Thomas Nugent; Jeffrey M Linnen; Mark J Delorey; Jennifer A Lehman; Erin N Boswell; J Erin Staples; Marc Fischer
Journal:  J Infect Dis       Date:  2010-12-15       Impact factor: 5.226

2.  Evaluation for West Nile Virus (WNV) RNA in urine of patients within 5 months of WNV infection.

Authors:  Steven A Baty; Katherine B Gibney; J Erin Staples; Andrean Bunko Patterson; Craig Levy; Jennifer Lehman; Tricia Wadleigh; Jamie Feld; Robert Lanciotti; C Thomas Nugent; Marc Fischer
Journal:  J Infect Dis       Date:  2012-03-20       Impact factor: 5.226

3.  Current practices and evaluation of screening solid organ donors for West Nile virus.

Authors:  R J Nett; M J Kuehnert; M G Ison; J P Orlowski; M Fischer; J E Staples
Journal:  Transpl Infect Dis       Date:  2012-05-20       Impact factor: 2.228

4.  Characteristics of the rash associated with West Nile virus fever.

Authors:  Dayna D Ferguson; Ken Gershman; Adrienne LeBailly; Lyle R Petersen
Journal:  Clin Infect Dis       Date:  2005-09-12       Impact factor: 9.079

5.  Evaluation of efficacy and human health risk of aerial ultra-low volume applications of pyrethrins and piperonyl butoxide for adult mosquito management in response to West Nile virus activity in Sacramento County, California.

Authors:  Paula A Macedo; Jerome J Schleier; Marcia Reed; Kara Kelley; Gary W Goodman; David A Brown; Robert K D Peterson
Journal:  J Am Mosq Control Assoc       Date:  2010-03       Impact factor: 0.917

6.  CSF findings in 250 patients with serologically confirmed West Nile virus meningitis and encephalitis.

Authors:  K L Tyler; J Pape; R J Goody; M Corkill; B K Kleinschmidt-DeMasters
Journal:  Neurology       Date:  2005-12-28       Impact factor: 9.910

7.  Nucleic acid testing for west nile virus RNA in plasma enhances rapid diagnosis of acute infection in symptomatic patients.

Authors:  Peter A G Tilley; Julie D Fox; Gayatri C Jayaraman; Jutta K Preiksaitis
Journal:  J Infect Dis       Date:  2006-04-04       Impact factor: 5.226

8.  Neurocognitive and functional outcomes in persons recovering from West Nile virus illness.

Authors:  James J Sejvar; Aaron T Curns; Leonie Welburg; James F Jones; Louisa M Lundgren; Lucile Capuron; John Pape; William C Reeves; Grant L Campbel
Journal:  J Neuropsychol       Date:  2008-09       Impact factor: 2.864

9.  Virus and antibody dynamics in acute west nile virus infection.

Authors:  Michael P Busch; Steven H Kleinman; Leslie H Tobler; Hany T Kamel; Philip J Norris; Irina Walsh; Jose L Matud; Harry E Prince; Robert S Lanciotti; David J Wright; Jeffrey M Linnen; Sally Caglioti
Journal:  J Infect Dis       Date:  2008-10-01       Impact factor: 5.226

10.  Experimental infection of North American birds with the New York 1999 strain of West Nile virus.

Authors:  Nicholas Komar; Stanley Langevin; Steven Hinten; Nicole Nemeth; Eric Edwards; Danielle Hettler; Brent Davis; Richard Bowen; Michel Bunning
Journal:  Emerg Infect Dis       Date:  2003-03       Impact factor: 6.883

View more
  225 in total

Review 1.  Current trends in West Nile virus vaccine development.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2014-04-01       Impact factor: 5.217

Review 2.  The innate immune playbook for restricting West Nile virus infection.

Authors:  Kendra M Quicke; Mehul S Suthar
Journal:  Viruses       Date:  2013-10-30       Impact factor: 5.048

3.  Genotypic and phenotypic characterization of West Nile virus NS5 methyltransferase mutants.

Authors:  Jaclyn A Kaiser; Huanle Luo; Steven G Widen; Thomas G Wood; Claire Y-H Huang; Tian Wang; Alan D T Barrett
Journal:  Vaccine       Date:  2019-10-11       Impact factor: 3.641

4.  MicroRNA reduction of neuronal West Nile virus replication attenuates and affords a protective immune response in mice.

Authors:  Terza Brostoff; Patricia A Pesavento; Christopher M Barker; Joan L Kenney; Elizabeth A Dietrich; Nisha K Duggal; Angela M Bosco-Lauth; Aaron C Brault
Journal:  Vaccine       Date:  2016-09-13       Impact factor: 3.641

Review 5.  Biochemistry and Molecular Biology of Flaviviruses.

Authors:  Nicholas J Barrows; Rafael K Campos; Kuo-Chieh Liao; K Reddisiva Prasanth; Ruben Soto-Acosta; Shih-Chia Yeh; Geraldine Schott-Lerner; Julien Pompon; October M Sessions; Shelton S Bradrick; Mariano A Garcia-Blanco
Journal:  Chem Rev       Date:  2018-04-13       Impact factor: 60.622

6.  Isolation of West Nile virus from urine samples of patients with acute infection.

Authors:  Luisa Barzon; Monia Pacenti; Elisa Franchin; Laura Squarzon; Alessandro Sinigaglia; Sebastian Ulbert; Riccardo Cusinato; Giorgio Palù
Journal:  J Clin Microbiol       Date:  2014-06-20       Impact factor: 5.948

Review 7.  DNA-launched live-attenuated vaccines for biodefense applications.

Authors:  Peter Pushko; Igor S Lukashevich; Scott C Weaver; Irina Tretyakova
Journal:  Expert Rev Vaccines       Date:  2016-04-25       Impact factor: 5.217

8.  Effect of aerial insecticide spraying on West Nile virus disease--north-central Texas, 2012.

Authors:  Duke J Ruktanonchai; Shelley Stonecipher; Nicole Lindsey; Janet McAllister; Satish K Pillai; Kalanthe Horiuchi; Mark Delorey; Brad J Biggerstaff; Tom Sidwa; James Zoretic; Roger Nasci; Marc Fischer; Susan L Hills
Journal:  Am J Trop Med Hyg       Date:  2014-04-28       Impact factor: 2.345

9.  Transmission of West Nile and five other temperate mosquito-borne viruses peaks at temperatures between 23°C and 26°C.

Authors:  Marta S Shocket; Anna B Verwillow; Mailo G Numazu; Hani Slamani; Jeremy M Cohen; Fadoua El Moustaid; Jason Rohr; Leah R Johnson; Erin A Mordecai
Journal:  Elife       Date:  2020-09-15       Impact factor: 8.140

Review 10.  Reducing West Nile Virus Risk Through Vector Management.

Authors:  Roger S Nasci; John-Paul Mutebi
Journal:  J Med Entomol       Date:  2019-10-28       Impact factor: 2.278

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.